Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf Psilocybin clears biggest depression test yet, but Compass stock falls amid chatter about adverse events, durability Immatics' cell therapy blasts solid tumors in phase 1, but durability spooks investors. Will dialing up the dose help? Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success Intima Bioscience poaches ex-Ichnos CEO with Gilead, Novartis resume to lead phase 1/2 asset After snapping up Parexel with Goldman Sachs, EQT doubles down on healthcare with Life Sciences Partners buyout Biogen's Aduhelm records one patient death. Is the controversial Alzheimer's drug to blame? GE Healthcare to become standalone company after conglomerate completes 3-way split Truveta's health data platform launches with $200M, insights on COVID breakthrough infections Featured Story | By Ben Adams The future of cell therapy is allogenic, it seems, as Poseida has decided to back away from work on its autologous candidate. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement on a symptom scale. But the stock fell in the wake of the news amid discussion of adverse events and durability. read more By Nick Paul Taylor Immatics has delivered evidence that its TCR-engineered cell therapies can move the needle in solid tumors, revealing 50% of heavily pretreated patients responded to its candidate despite taking less than the target dose. The challenge now? To improve the durability of the responses. read more Sponsored by: IPM.ai Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention. read more By Kyle LaHucik Alessandro Riva is making another move. The former Novartis and Gilead oncology head, who spent the past two years at Glenmark spinoff Ichnos, will step into the CEO role at hush-hush startup Intima Bioscience as the biotech goes through a phase 1/2 trial with its lead CRISPR gene editing cell therapy in gastrointestinal and colon cancers. read more By Ben Adams The ink in EQT’s checkbook is still not quite dry from the $8.5 billion it and Goldman Sachs spent on CRO Parexel back in March, but it will need a fresh page as it snaps up a major European healthcare venture capital firm. read more By Angus Liu Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a death reported to the FDA Adverse Event Reporting System (FAERS) will likely trigger more doubts around its use. read more By Andrea Park After years of speculation and false starts, General Electric is officially spinning off its healthcare business into an independent company. read more By Rebecca Torrence Truveta was created earlier this year by some of the country's biggest health systems to pool and analyze de-identified patient data. Tuesday, the platform launched with $200 million in funding and new results from an analysis of those patient data on COVID-19 breakthrough infections. read more Resources Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Blue Matter Consulting Paper describing how the chronic insomnia market offers big lessons for any biopharma company thinking about getting into digital therapeutics in any therapeutic area. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: TransPerfect Life Sciences Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Pharma Meeting Pros Summit November 3-4, 2021 | Atlantic City, NJ & Virtual Fierce Diversity, Equity & Inclusion Summit November 9–10, 2021 | Virtual Event Drug Development Boot Camp® 2021 VIRTUAL November 17-18, 2021 Learn impact of pricing, competitive assessment, epidemiology November 17-18, 2021 | Live & Online Fierce New Product Planning Summit December 1-2, 2021 | Boston, MA Fierce Launch Readiness for Medical Affairs & Communications Teams December 1-2, 2021 | Boston, MA Learn how therapeutics are successfully launched and commercialized December 1-2, 2021 | Live & Online 2nd Annual Symposium on Translational Medicine and Biomanufacturing December 2—3, 2021 Fierce Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Virtual European Healthcare Compliance Certificate Program January 24-28, 2022 Fierce Biotech Forum 2022 | Virtual Event Fierce Pharma Drug Safety Summit February 8-9, 2022 | Location TBD Fierce Medical Affairs Strategic Summit (MASS) East April 2022 | Location TBD | 